pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past.

Antibody 90

Antibody Life Science Development Regulation 90

Drug Discovery World

OCTOBER 16, 2023

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

MAY 6, 2022

In this interview, Xtalks spoke with experts from eClinical Solutions , Katrina Rice, Chief Delivery Officer, Data Services; and Diane Lacroix, Vice President, Clinical Data Management, about clinical data management for modern day digital clinical trials. elluminate Clinical Trial Management System (CTMS) Insights.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Life Science 98

pharmaphorum

MARCH 12, 2021

That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s Clinical Research Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharma companies seem to be gradually improving on this. Listening to patients.

Trials 132

Trials Research Pharma Companies Clinical Trials 132

XTalks

MAY 11, 2023

The need to develop points in time where patient insights can inform clinical research is really critical. Moreover, we embed patient centricity far beyond clinical development. Development is just the beginning. ” It’s actually part of the process.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

pharmaphorum

NOVEMBER 3, 2022

Beyond digital clinical measures, digital solutions are maturing to address major challenges facing clinical research and offer enormous promise to support the key performance indicators (KPIs) for every member of our industry. Pharma companies with more mature digital strategies are able to focus on questions of scale.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Medicine 80

pharmaphorum

MAY 7, 2021

This philosophy was behind Xperiome’s recent decision to split into two different functions – Raremark, a community where patients and carers can share their experiences of living with rare diseases, and Xperiome, which leverages those insights for pharma companies looking to develop drugs for these conditions. About the author.

Development 125

Development Pharma Companies Clinical Trials Clinical Trials 125

pharmaphorum

AUGUST 24, 2022

The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials , recommends sponsors develop and submit a race and ethnicity diversity plan early in clinical development. Community-led.

Clinical Trials 109

Clinical Trials Clinical Trials Trials Development 109

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

OCTOBER 10, 2022

Such partnerships are mutually beneficial for all involved parties as pharma companies have a wealth of data, insight, and connections at their disposal, resources that can play a central role in enabling early diagnosis for the NHS and patients.

Development 98

Development Research Marketing Life Science 98

Drug Discovery World

OCTOBER 7, 2022

RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.

HR 52

HR Research Drugs Development 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. Axol Bioscience – Based in the U.K.,

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52